This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Comenzo RL, Fein DE, Hassoun H, Bello C, Chou JF, Devlin S et al. Long-term outcomes of patients with systemic light chain amyloidosis (AL) treated at diagnosis with risk-adapted stem cell transplant and consolidation with novel agents. ASH Annu Meet Abstr 2012; 120: 3150.
DiPersio JF, Stadtmauer EA, Nademanee A, Micallef IN, Stiff PJ, Kaufman JL et al. Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma. Blood 2009; 113: 5720–5726.
Douglas KW, Parker AN, Hayden PJ, Rahemtulla A, D'Addio A, Lemoli RM et al. Plerixafor for PBSC mobilisation in myeloma patients with advanced renal failure: safety and efficacy data in a series of 21 patients from Europe and the USA. Bone Marrow Transplant 2012; 47: 18–23.
Dunn D, Vikas P, Jagasia M, Savani BN . Plerixafor in AL amyloidosis: improved graft composition and faster lymphocyte recovery after auto-SCT in patient with end-stage renal-disease. Bone Marrow Transplant 2012; 47: 1136–1137.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
RLC: consultant/scientific advisor, Takeda, Prothena; clinical research funding, Takeda, Prothena, Teva. The other authors declare no conflict of interest.
Rights and permissions
About this article
Cite this article
Kaul, E., Shah, G., Chaulagain, C. et al. Plerixafor and G-CSF for autologous stem cell mobilization in AL amyloidosis. Bone Marrow Transplant 49, 1233 (2014). https://doi.org/10.1038/bmt.2014.117
Published:
Issue Date:
DOI: https://doi.org/10.1038/bmt.2014.117
This article is cited by
-
Impact of prior melphalan exposure on stem cell collection in light chain amyloidosis
Bone Marrow Transplantation (2018)
-
Stem cell transplantation in patients with systemic AL amyloidosis referred for transplant after suboptimal responses to bortezomib-based initial therapy
Bone Marrow Transplantation (2017)